 "GlaxoSmithKline Pharma Q3 profit dips 33 per cent at Rs 53 crore")
GlaxoSmithKline Pharmaceuticals on Saturday reported 32.91 per cent decline in net profit at Rs 52.95 crore for the quarter ended December 31, on account of mandatory price cuts as well as demonetisation.
The company had posted a net profit of Rs 78.93 crore for the same period of previous financial year.
Total income from operations declined to Rs 706.38 crore in the third quarter of 2016-17 from 750.69 crore during the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.
"The performance of the quarter has been impacted by number of factors. The mandatory price reductions experienced in the earlier quarters of the year have adversely impacted growth by 5 per cent in the current quarter," GlaxoSmithKline Managing Director A Vaidheesh said.
The estimated impact of demonetisation adversely impacted performance further by 5 per cent from the company's pharmaceutical product portfolio which is predominantly within acute care as well as from consumer brands, he added.
The quarter was also impacted by supply constraints, Vaidheesh said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%